Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Pleural Effusion, Malignant 2Mesothelioma, Malignant 2Triple Negative Breast Neoplasms 1Recurrence 1Prostatic Neoplasms 1NSCLC 1

Interventions

pembrolizumab 48Nivolumab 22Cyclophosphamide 10Carboplatin 10spartalizumab 8atezolizumab 7Gemcitabine 7130-nm albumin-bound paclitaxel 7fludarabine 6Cisplatin 6Ipilimumab 5durvalumab 4budigalimab 4avelumab 4Pemetrexed 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Leucovorin 4Irinotecan 4Interleukin-2 4Immune Checkpoint Inhibitors 4Docetaxel 4Bevacizumab 4cemiplimab 3cabozantinib 3aldesleukin 3Standard of Care 3Specimen Handling 3Oxaliplatin 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Pharmaceutical Preparations × Thoracic × Clear all
NCT03401385 2025-10-21

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Daiichi Sankyo

Phase 1 Active not recruiting
890 enrolled
BreastThoracic

Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡